Terence Flynn
Stock Analyst at Morgan Stanley
(4.23)
# 433
Out of 5,111 analysts
228
Total ratings
59.83%
Success rate
11.88%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $190 → $197 | $208.77 | -5.64% | 26 | Dec 12, 2025 | |
| PFE Pfizer | Maintains: Equal-Weight | $32 → $28 | $25.26 | +10.85% | 20 | Dec 12, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $37 | $54.13 | -31.65% | 12 | Dec 12, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $100 → $102 | $98.45 | +3.61% | 20 | Dec 12, 2025 | |
| GPCR Structure Therapeutics | Maintains: Overweight | $120 → $125 | $60.76 | +105.74% | 2 | Dec 12, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $329 → $304 | $328.35 | -7.42% | 11 | Dec 12, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $261 → $269 | $223.60 | +20.30% | 19 | Dec 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $516 → $564 | $454.12 | +24.20% | 3 | Dec 5, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,171 → $1,290 | $1,056.59 | +22.09% | 23 | Nov 24, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $54 → $26 | $11.42 | +127.77% | 4 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $9 | $7.07 | +27.30% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $18.51 | -18.96% | 6 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $54 | $38.65 | +39.72% | 13 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $131 | $92.99 | +40.88% | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $328 → $435 | $505.99 | -14.03% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $11.17 | +96.96% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $23 | $22.22 | +3.51% | 8 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $12.00 | -8.33% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $57.13 | -43.99% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $9.35 | +17.65% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.15 | +272.96% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $170.39 | +155.88% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $393.38 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.44 | - | 1 | Jul 21, 2017 |
Johnson & Johnson
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $190 → $197
Current: $208.77
Upside: -5.64%
Pfizer
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $32 → $28
Current: $25.26
Upside: +10.85%
Bristol-Myers Squibb Company
Dec 12, 2025
Maintains: Underweight
Price Target: $36 → $37
Current: $54.13
Upside: -31.65%
Merck & Co.
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $100 → $102
Current: $98.45
Upside: +3.61%
Structure Therapeutics
Dec 12, 2025
Maintains: Overweight
Price Target: $120 → $125
Current: $60.76
Upside: +105.74%
Amgen
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $329 → $304
Current: $328.35
Upside: -7.42%
AbbVie
Dec 12, 2025
Maintains: Overweight
Price Target: $261 → $269
Current: $223.60
Upside: +20.30%
Vertex Pharmaceuticals
Dec 5, 2025
Maintains: Overweight
Price Target: $516 → $564
Current: $454.12
Upside: +24.20%
Eli Lilly and Company
Nov 24, 2025
Maintains: Overweight
Price Target: $1,171 → $1,290
Current: $1,056.59
Upside: +22.09%
Biohaven
Nov 18, 2025
Maintains: Overweight
Price Target: $54 → $26
Current: $11.42
Upside: +127.77%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $7.07
Upside: +27.30%
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $18.51
Upside: -18.96%
Oct 10, 2025
Maintains: Overweight
Price Target: $55 → $54
Current: $38.65
Upside: +39.72%
Oct 10, 2025
Maintains: Overweight
Price Target: $133 → $131
Current: $92.99
Upside: +40.88%
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $328 → $435
Current: $505.99
Upside: -14.03%
Aug 15, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $11.17
Upside: +96.96%
Aug 7, 2025
Maintains: Overweight
Price Target: $22 → $23
Current: $22.22
Upside: +3.51%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $12.00
Upside: -8.33%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $57.13
Upside: -43.99%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $9.35
Upside: +17.65%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.15
Upside: +272.96%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $170.39
Upside: +155.88%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $393.38
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $9.44
Upside: -